Breaking News, Collaborations & Alliances

Merck Partners with Vector Institute to Advance AI in Healthcare

Gains access to Vector Institute's AI network, talent and research.

Merck & Co., known as MSD outside the United States and Canada, has entered into a multi-year agreement with the Vector Institute in Toronto, an independent not-for-profit corporation dedicated to advancing the field of artificial intelligence (AI) through research, allowing Merck Canada to gain access to Vector’s research capabilities and expertise in AI and engage with its ecosystem to drive innovation in healthcare.
 
As such, Merck Canada will have the opportunity to tap into Vector Institute’s network of AI researchers, engineers, and startups. This interaction aims to provide a fertile ground for Merck Canada to exchange ideas, connect with premier talent, and stay abreast of the latest advancements in AI technologies and methods applicable to life sciences.
 
“We are excited about the opportunities that our collaboration with the Vector Institute brings to Merck Canada. Together, we will explore the potential of AI to transform the way we address healthcare challenges and deliver impactful solutions that benefit patients in Canada and beyond,” said Marwan Akar, Managing Director at Merck Canada.
 
“We recognize the power of AI in driving customer engagement at Merck. As digital transformation continues to redefine what’s possible in healthcare, we look to organizations like Vector to help us find innovative ways to leverage machine learning and deep learning to improve health outcomes,” added Abhishek Narayan Singh, Vice President, Data Science, at Merck.
 
“Canadians deserve modern health care solutions using the best technologies and tools available. We are thrilled to welcome Merck Canada to Vector’s sponsor community.  Together with Vector, Merck’s strong commitment to innovation in health will help realize AI capabilities that can be life-changing for patients,” said Tony Gaffney, President and CEO, Vector Institute.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters